OncoCyte Corp Net Income vs. Revenue
| OCX Stock | USD 2.32 0.07 2.93% |
Net Loss | First Reported 2013-12-31 | Previous Quarter -4.5 M | Current Value -13.5 M | Quarterly Volatility 10.1 M |
For OncoCyte Corp profitability analysis, we use financial ratios and fundamental drivers that measure the ability of OncoCyte Corp to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well OncoCyte Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between OncoCyte Corp's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of OncoCyte Corp over time as well as its relative position and ranking within its peers.
OncoCyte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OncoCyte Corp. If investors know OncoCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OncoCyte Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.44) | Revenue Per Share 0.066 | Quarterly Revenue Growth (0.73) | Return On Assets (0.19) | Return On Equity (1.65) |
The market value of OncoCyte Corp is measured differently than its book value, which is the value of OncoCyte that is recorded on the company's balance sheet. Investors also form their own opinion of OncoCyte Corp's value that differs from its market value or its book value, called intrinsic value, which is OncoCyte Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OncoCyte Corp's market value can be influenced by many factors that don't directly affect OncoCyte Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OncoCyte Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if OncoCyte Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OncoCyte Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
OncoCyte Corp Revenue vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining OncoCyte Corp's current stock value. Our valuation model uses many indicators to compare OncoCyte Corp value to that of its competitors to determine the firm's financial worth. OncoCyte Corp is regarded second in net income category among its peers. It is regarded third in revenue category among its peers . OncoCyte Corp reported Net Loss of (27.78 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the OncoCyte Corp's earnings, one of the primary drivers of an investment's value.OncoCyte Revenue vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
OncoCyte Corp |
| = | (27.78 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
OncoCyte Corp |
| = | 1.5 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
OncoCyte Revenue vs Competition
OncoCyte Corp is regarded third in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 298.33 Million. OncoCyte Corp adds roughly 1.5 Million in revenue claiming only tiny portion of equities under Health Care industry.
OncoCyte Corp Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in OncoCyte Corp, profitability is also one of the essential criteria for including it into their portfolios because, without profit, OncoCyte Corp will eventually generate negative long term returns. The profitability progress is the general direction of OncoCyte Corp's change in net profit over the period of time. It can combine multiple indicators of OncoCyte Corp, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 49 K | 51.5 K | |
| Operating Income | -25.1 M | -26.4 M | |
| Income Before Tax | -24.9 M | -26.1 M | |
| Net Loss | -27.8 M | -29.2 M | |
| Net Loss | -20.9 M | -21.9 M | |
| Total Other Income Expense Net | 281 K | 295.1 K | |
| Net Loss | -66.1 M | -62.8 M | |
| Income Tax Expense | 2.9 M | 5.1 M | |
| Interest Income | 35.6 K | 33.9 K | |
| Net Interest Income | 96 K | 100.8 K | |
| Non Operating Income Net Other | -618.7 K | -649.6 K | |
| Change To Netincome | 27.7 M | 29 M | |
| Net Loss | (3.63) | (3.81) | |
| Income Quality | 0.84 | 0.50 | |
| Net Income Per E B T | 1.12 | 1.26 |
OncoCyte Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on OncoCyte Corp. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of OncoCyte Corp position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the OncoCyte Corp's important profitability drivers and their relationship over time.
Use OncoCyte Corp in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OncoCyte Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OncoCyte Corp will appreciate offsetting losses from the drop in the long position's value.OncoCyte Corp Pair Trading
OncoCyte Corp Pair Trading Analysis
The ability to find closely correlated positions to OncoCyte Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OncoCyte Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OncoCyte Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OncoCyte Corp to buy it.
The correlation of OncoCyte Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OncoCyte Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OncoCyte Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OncoCyte Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your OncoCyte Corp position
In addition to having OncoCyte Corp in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SPAC Thematic Idea Now
SPAC
Entities that are involved in raising capital, merging with and acquiring companies, and investing in private equity through leveraged buyouts. The SPAC theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SPAC Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.